HJF to develop herpes virus vaccines The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) and Citranvi Biosciences have signed an exclusive licensing agreement to develop vaccine technologies to prevent cytomegalovirus and Epstein-Barr virus infections.
Reaction Biology, 4HF Biotec offer new cell-based services Reaction Biology and 4HF Biotec announced that they are offering a new cell-based service that will give customers a comprehensive understanding of their candidates. The service will combine Reaction's ProLiFiler cell assay service with 4HF's Biomarker Analysis and Mode of Action (MoA) Finder tools
Endo to acquire BioSpecifics Endo will acquire all shares of BioSpecifics Technologies for $88.50 per share, or an estimated total of $540 million. As part of the acquisition, BioSpecifics will receive a royalty stream from Endo's collagenase-based therapies, including Xiaflex and Qwo, which were developed by BioSpecifics.
Precigen nabs FDA nod for manufacturing UltraCAR-T therapies Precigen has been granted clearance by the U.S. Food and Drug Administration (FDA) for its UltraPorator system. The system also had a successful technology transfer to clinical sites and will be used as a manufacturing device for Precigen's investigational UltraCAR-T therapies.